Silexion Therapeutics ( ($SLXN) ) has provided an update. On May 22, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company, received ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) ...

SEATTLE, WA - May 12, 2025 - The KD Hall Foundation, a Washington-based nonprofit advancing leadership, education, and mental health for women and girls, will celebrate 10 years of transformative ...

Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both ...

Bleomycins are a family of glycopeptide antibiotics with antitumour activity. They are used clinically in combination chemotherapy against lymphomas, squamous-cell carcinomas and germ-cell tumours.

May 9, 2025 -- Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated, dual PARP ...

HLS Therapeutics Inc. (HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into an ...

Senators Shelley Moore Capito, R-W.Va., and Jeanne Shaheen, D-N.H., reintroduced the Access to Prescription Digital Therapeutics (PDT) Act on Thursday to expand access to software-based treatments.

ATA Action, the advocacy arm of the American Telemedicine Association, is supporting a new bipartisan bill that could bring FDA-authorized prescription digital therapeutics (PDTs) under Medicare and ...